{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:23:01Z","timestamp":1782915781683,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VENI 016.115.155"],"award-info":[{"award-number":["VENI 016.115.155"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.euroneuro.2021.07.005","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T16:59:57Z","timestamp":1628009997000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder"],"prefix":"10.1016","volume":"53","author":[{"given":"Marisol J.","family":"Voncken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella J.M.","family":"Niesten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Schruers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim P.C.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2021.07.005_bib0001","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1037\/ccp0000306","article-title":"Treatment of social approach processes in adults with social anxiety disorder","volume":"86","author":"Alden","year":"2018","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0002","series-title":"Interpersonal Processes in the Anxiety disorders: Implications for Understanding Psychopathology and Treatment","first-page":"125","article-title":"Interpersonal processes in social anxiety disorder","author":"Alden","year":"2010"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0003","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.yhbeh.2006.06.018","article-title":"The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior","volume":"50","author":"Bartz","year":"2006","journal-title":"Horm. Behav."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0004","first-page":"301","article-title":"Social effects of oxytocin in humans: context and person matter","volume":"15","author":"Bartz","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1022812227606","article-title":"Validity of two questionnaires to assess social fears: the Dutch social phobia and anxiety inventory and the blushing, trembling and sweating questionnaire","volume":"21","author":"B\u00f6gels","year":"1999","journal-title":"J. Psychopathol. Behav. Assess"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/1088868310363594","article-title":"Oxytocin and human social behavior","volume":"14","author":"Campbell","year":"2010","journal-title":"Pers. Soc. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0007","series-title":"The Essential Handbook of Social Anxiety For Clinicians","first-page":"193","article-title":"A cognitive perspective on social phobia","author":"Clark","year":"2005"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2019.17.1.1","article-title":"The role of intranasal oxytocin in anxiety and depressive disorders: a systematic review of randomized controlled trials","volume":"17","author":"De Cagna","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40263-019-00669-5","article-title":"Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder","volume":"33","author":"Dos Santos","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0010","first-page":"89","article-title":"Verdere validering van de positive and negative affect schedule (PANAS) en vergelijking van twee Nederlandstalige versies\u00a0=\u00a0further validation of the positive and negative affect schedule (PANAS) and comparison of two Dutch versions","volume":"34","author":"Engelen","year":"2006","journal-title":"Gedrag Gezondheid: Tijdschrift voor Psychologie en Gezondheid"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0011","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/2167702614527948","article-title":"Attachment style moderates the effects of oxytocin on social behaviors and cognitions during social rejection: applying an RDoC framework to social anxiety","volume":"2","author":"Fang","year":"2014","journal-title":"Clin. Psychol. Sci."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biopsycho.2017.05.015","article-title":"Working hard for oneself or others: effects of oxytocin on reward motivation in social anxiety disorder","volume":"127","author":"Fang","year":"2017","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0013","series-title":"Structured Clinical Interview For DSM-IV Axis I Disorders - Patient Edition (SCID-I\/P, Version 2.0)","author":"First","year":"1996"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0014","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.yhbeh.2012.01.002","article-title":"A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions","volume":"61","author":"Gaustella","year":"2012","journal-title":"Horm. Behav."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0015","series-title":"Gestructureerd Klinisch Interview Voor De Vaststelling Van DSM-IV As I Stoornissen, Nederlandse vertaling, SCID-I","author":"Groenestijn","year":"1997"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0016","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.psyneuen.2009.01.005","article-title":"A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder","volume":"34","author":"Guastella","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0017","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yfrne.2009.05.005","article-title":"Oxytocin, vasopressin, and human social behavior","volume":"30","author":"Heinrichs","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0018","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/16506070701421313","article-title":"Cognitive factors that maintain social anxiety disorder: a comprehensive model and its treatment implications","volume":"36","author":"Hofmann","year":"2007","journal-title":"Cogn. Behav. Ther."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biopsych.2015.02.002","article-title":"Translating oxytocin neuroscience to the clinic: a National Institute of Mental Health perspective","volume":"79","author":"Insel","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr. Med."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0022","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2017.08.041","article-title":"Meta-analytic review of the effects of a single dose of intranasal oxytocin on threat processing in humans","volume":"225","author":"Leppanen","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0023","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41386-019-0582-6","article-title":"Kinetics of oxytocin effects on amygdala and striatal reactivity vary between women and men","volume":"45","author":"Lieberz","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00019053-200018010-00003","article-title":"Social phobia. Epidemiology and cost of illness","volume":"18","author":"Lipsitz","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","article-title":"Response rates for CBT for anxiety disorders: need for standardized criteria","volume":"42","author":"Loerinc","year":"2015","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10673220903523615","article-title":"The peptide that binds: a systematic review of oxycotin and its prosocial effects in humans","volume":"18","author":"MacDonald","year":"2010","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0027","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1037\/0022-3514.64.6.1000","article-title":"Anxiety and self-disclosure: toward a motivational model","volume":"64","author":"Meleshko","year":"1993","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0028","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.nmd.0000253843.70149.9a","article-title":"A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders","volume":"195","author":"Norton","year":"2007","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0029","series-title":"Mini International Neuropsychiatric Interview: Nederlandse Versie 5.0.0","author":"Overbeek","year":"1999"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/jrpe.1998.2219","article-title":"Mediators of social rejection in social anxiety: similarity, self-disclosure, and overt signs of anxiety","volume":"32","author":"Papsdorf","year":"1998","journal-title":"J. Res. Personal."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0031","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tics.2020.03.008","article-title":"An allostatic theory of oxytocin","volume":"24","author":"Quintana","year":"2020","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0032","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D Scale: a self-report depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl. Psychol. Meas."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0033","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.psyneuen.2013.09.022","article-title":"Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction","volume":"39","author":"Rilling","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0034","series-title":"The Wiley Blackwell Handbook of Social Anxiety Disorder","first-page":"366","article-title":"Examining the controversy surrounding social skills in social anxiety disorder: the state of the literature","author":"Schneider","year":"2014"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0035","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0036","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1176\/appi.ps.53.6.714","article-title":"Quality of life in social anxiety disorder compared with panic disorder and the general population","volume":"53","author":"Simon","year":"2002","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0037","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","article-title":"Social anxiety disorder","volume":"371","author":"Stein","year":"2008","journal-title":"Lancet North Am. Ed."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0038","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2018.10.008","article-title":"Complementary neural circuits for divergent effects of oxytocin: social approach versus social anxiety","volume":"85","author":"Steinman","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0039","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.psyneuen.2019.04.019","article-title":"Null results of oxytocin and vasopressin administration across a range of social cognitive and behavioral paradigms: evidence from a randomized controlled trial","volume":"107","author":"Tabak","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0005-7916(02)00021-6","article-title":"The effect of situational structure on the social performance of socially anxious and non-anxious participants","volume":"33","author":"Thompson","year":"2002","journal-title":"J. Behav. Ther. Exp. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0041","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1037\/1040-3590.1.1.35","article-title":"An empirically derived inventory to measure social fears and anxiety: the social phobia and anxiety inventory","volume":"1","author":"Turner","year":"1989","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0042","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.janxdis.2008.02.001","article-title":"Social performance deficits in social anxiety disorder: reality during conversation and biased perception during speech","volume":"22","author":"Voncken","year":"2008","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0043","series-title":"Socially Anxious Individuals Get a Second Chance After Being Disliked At First Sight: The Role of Self-Disclosure in the Development of Likeability in Sequential Social Contact","author":"Voncken","year":"2012"},{"key":"10.1016\/j.euroneuro.2021.07.005_bib0044","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1037\/0022-3514.54.6.1063","article-title":"Development and validation of brief measures of positive and negative affect: the PANAS scales","volume":"54","author":"Watson","year":"1988","journal-title":"J. Pers. Soc. Psychol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21002741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21002741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T21:13:09Z","timestamp":1640207589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X21002741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"alternative-id":["S0924977X21002741"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.07.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}